Dossier assessment
Apixaban - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Report documents
-
Extract of dossier assessment
Apixaban - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
-
Dossier assessment
Apixaban - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Press releases
Apixaban in atrial fibrillation: indications of considerable added benefit
Fewer strokes and embolisms than with ASA / Fewer deaths, strokes and bleeding events in people over the age of 65 years in comparison with warfarin
Additional information
IQWiG health information
Project details
- Project no.
- A12-20
- Commission
- Commission awarded on 18.12.2012 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Prevention and screening, Head and nerves
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Apixaban (extension of approval) - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed
-
Dossier assessment
Apixaban - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed